1 week Ago By [email protected] (MENAFN)
All other provisions of the Debentures will remain unchanged and fully in effect during the extension period. The amendment remains subject to the TSX Venture Exchange acceptance as well as execution of formal documentation. All monies quoted in this press release shall be stated and paid in lawful money of Canada.
About DIAGNOS DIAGNOS is a publicly traded Canadian corporation dedicated to early detection of critical eye-related health problems. By leveraging Artificial Intelligence, DIAGNOS aims to provide more information to healthcare clinicians to enhance diagnostic accuracy, streamline workflows, and improve patient outcomes on a global scale. Additional information is available at and This news release contains forward-looking information.
There can be no assurance that forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in these statements. DIAGNOS disclaims any intention or obligation to publically update or revise any forward-looking information, whether as a result of new information, future events or otherwise. The forward-looking information contained in this news release is expressly qualified by this cautionary statement.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. MENAFN31032025004107003653ID1109376121 Legal Disclaimer: MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article.
If you have any complaints or copyright issues related to this article, kindly contact the provider above..
